Low incidence of secondary neoplasia after autotransplantation for lymphoproliferative disease: The role of pre-transplant therapy

Clinical Transplantation

Volumn 22, Issue 2, 2008, Pages 191-199

  Laurenti, Luca ^a   Tarnani, Michela ^a   Chiusolo, Patrizia ^a   La Torre, Giuseppe ^a   Garzia, Mariagrazia ^a   Zollino, Marcella ^a   Zini, Gina ^a   Balducci, Mario ^a   Leone, Giuseppe ^a   Sica, Simona ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Autologous transplant; Cord blood; Lymphoproliferative disorders; Myelodysplastic syndrome

Indexed keywords

ALKYLATING AGENT; BLEOMYCIN; BUSULFAN; CARBOPLATIN; CARMUSTINE; CD20 ANTIBODY; CHLORMETHINE; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DAUNORUBICIN; DEXAMETHASONE; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; FLUOROURACIL; FOLINIC ACID; IDARUBICIN; IFOSFAMIDE; MELPHALAN; METHOTREXATE; METHYLPREDNISOLONE; MITOXANTRONE; PREDNISONE; PROCARBAZINE; RITUXIMAB; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; AUTOTRANSPLANTATION; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER RISK; CHRONIC LYMPHATIC LEUKEMIA; DISEASE ACTIVITY; DRUG MEGADOSE; FEMALE; GRAFT REJECTION; HODGKIN DISEASE; HUMAN; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MULTIVARIATE ANALYSIS; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PRIORITY JOURNAL; RISK FACTOR; SOLID TUMOR; UNIVARIATE ANALYSIS;

ADOLESCENT; ADULT; FEMALE; HUMANS; INCIDENCE; ITALY; KAPLAN-MEIERS ESTIMATE; LEUKEMIA, MYELOID, ACUTE; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; NEOPLASMS, SECOND PRIMARY; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PROPORTIONAL HAZARDS MODELS; RADIOTHERAPY; RETROSPECTIVE STUDIES; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS;

EID: 41049083911     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2007.00768.x     Document Type: Article

References (34)

1. Shimada K, Yokozawa T, Atsuta Y et al. Solid tumors after hematopoietic stem cell transplantation in Japan: Incidence, risk factors and prognosis. Bone Marrow Transplant 2005: 36: 115.
2. Rowley JD, Golomb HM, Vardiman JW et al. Nonrandom chromosome abnormalities in acute leukemia and dysmyelopoietic syndromes in patients with previously treated malignant disease. Blood 1981: 58: 759.
3. Pedersen-Bjergaard J, Philip P, Pedersen NT et al. Acute nonlymphocytic leukemia, preleukemia, and acute myeloproliferative syndrome secondary to treatment of other malignant diseases, II: Bone marrow cytology, cytogenetics, results of HLA typing, response to antileukemic chemotherapy, and survival in a total series of 55 patients. Cancer 1984: 54: 452.
4. Arthur DC, Bloomfield CD. Banded chromosome analysis in patients with treatment-associated acute nonlymphocytic leukemia. Cancer Genet Cytogenet 1984: 12: 189.
5. Thirman MJ, Larson RA. Therapy-related myeloid leukemia. Hematol Oncol Clin North Am 1996: 10: 293.
6. Baker KS, De For TE, Burns LJ et al. New malignancies after blood or marrow stem-cell transplantation in children and adults: Incidence and risk factors. J Clin Oncol 2003: 21: 1352.
7. Curtis RE, Rowlings PA, Deeg HJ et al. Solid cancers after bone marrow transplantation. N Engl J Med 1997: 336: 897.
8. Bathia S, Louie AD, Bathia R et al. Solid cancers after bone marrow transplantation. J Clin Oncol 2001: 19: 464.
9. Forrest DL, Nevill TJ, Naiman SC et al. Second malignancy following high-dose therapy and autologous stem cell transplantation: Incidence and risk factor analysis. Bone Marrow Transplant 2003: 32: 915.
10. Abbruzzese E, Radford JE, Miller JS et al. Detection of abnormal pretransplant clones in progenitor cells of patients who developed myelodysplasia after autologous transplantation. Blood 1999: 94: 1814.
11. Deeg J, SocièG. Malignancies after hematopoietic stem cell transplantation: Many questions, some answers. Blood 1998: 91: 1833.
12. Mauch PM, Kalish LA, Marcus KC et al. Second malignancies after treatment for laparotomy staged IA-IIIB Hodgkin's disease: Longterm analysis of risk factors and outcome. Blood 1996: 89: 3625.
13. Ng AK, Bernardo MPV, Wellwe E et al. Second malignancy after Hodgkin's disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factors. Blood 2002: 100: 1989.
14. Dores GM, Metayer C, Curtis RE et al. Second malignant neoplasm among long-term survivors of Hodgkin's disease: A population-based evaluation over 25 years. J Clin Oncol 2002: 20: 3484.
15. Darrington DL, Vose JM, Anderson JR et al. Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem cell transplantation for lymphoid malignancies. J Clin Oncol 1994: 12: 2527.
16. Miller JS, Arthur DC, Litz CE et al. Myelodysplastic syndrome after autologous bone marrow transplantation: An additional late complication of curative cancer therapy. Blood 1994: 83: 3780.
17. Milligan DW, Ruiz de Elvira MC, Kolb H-J et al. Secondary leukemia and myelodysplasia after autografting for lymphoma: Results from the EBMT. Br J Haematol 1999: 106: 1020.
18. Stone RM, Neuberg D, Soiffer R et al. Myelodysplastic syndrome as a late complication following autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol 1994: 12: 2535.
19. Harrison CN, Gregory W, Vaughan Hudson G et al. High-dose BEAM chemotherapy with autologous haematopoietic stem cell transplantation for Hodgkin's disease is inlikely to be associated with a major increased risk of secondary MDS/AML. Br J Cancer 1999: 81: 476.
20. Amigo ML, del Canizo MC, Rios A et al. Diagnosis of secondary myelodysplastic syndrome (MDS) following autologous transplantation should not be based only on morphological criteria used for diagnosis of de novo MDS. Bone Marrow Transplant 1999: 23: 997.
21. Laurenti L, Chiusolo P, Garzia MG et al. Periodic morphologic, cytogenetic and clonality evaluation after autologous peripheral blood progenitor cell transplantation in patients with lymphoproliferative malignancies. Haematologica 2002: 87: 59.
22. Armitage JO, Carbone PP, Connors JM et al. Treatment-related myelodysplasia and acute leukemia in non-Hodgkin's lymphoma patients. J Clin Oncol 2003: 21: 897.
23. Leone G, Mele L, Pulsoni A et al. The incidence of secondary leukemias. Haematologica 1999: 84: 937.
24. Wheeler C, Khurshid A, Ibrahim J et al. Incidence of post transplant myelodysplasia/acute leukemia in non-Hodgkin's lymphoma patients compared with Hodgkin's disease patients undergoing autologous transplantation following cyclophosphamide, carmustine, and etoposide (CBV). Leuk Lymphoma 2001: 40: 499.
25. White AD, Jones BM, Clark RE et al. Chromosome aberrations following cytotoxic therapy in patients in complete remission from lymphoma. Carcinogenesis 1992: 13: 1095.
26. Smith SM, Le Beau MM, Huo D et al. Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. Blood 2003: 102: 43.
27. Brown JR, Yeckes H, Friedberg JW et al. Increasing incidence of late second malignancies after conditioning with cyclophosphamide and total-body irradiation and autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol 2005: 23: 2208.
28. Friedberg JW, Neuberg D, Stone RM et al. Outcome of patients with myelodysplastic syndrome after autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol 1999: 17: 3128.
29. Bathia S, Ramsay NKC, Steinbuch M et al. Malignant neoplasm following bone marrow transplantation. Blood 1996: 87: 3633.
30. Krishnan A, Bathia S, Slovak ML et al. Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: An assessment of risk factors. Blood 2000: 95: 1588.
31. Pedersen-Bjergaard J, Andersen MK, Christiansen DH et al. Therapy-related acute myeloid leukemia and myelodysplasia after high-dose chemotherapy and autologous stem cell transplantation. Blood 2000: 95: 3273.
32. Milligan DW, Kochethu G, Dearden D et al. High incidence of myelodysplasia and secondary leukemia in UK Medical Research Council Pilot of autografting in chronic lymphocytic leukemia. Br J Haematol 2006: 133: 173.
33. Kalaycio M, Rybicki L, Pohlman B et al. Risk factors before autologous stem-cell transplantation for lymphoma predict for secondary myelodysplasia and acute myelogenous leukemia. J Clin Oncol 2006: 24: 3604.
34. Lenz G, Dreyling M, Schiegnitz E et al. Moderate increase of secondary hematologic malignancies after myeloablative radiochemotherapy and autologous stem-cell transplantation in patients with indolent lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group. J Clin Oncol 2004: 22: 4926.